<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745468</url>
  </required_header>
  <id_info>
    <org_study_id>P02 CABY1</org_study_id>
    <nct_id>NCT04745468</nct_id>
  </id_info>
  <brief_title>Study on CRP Apheresis After Coronary Bypass Surgery</brief_title>
  <acronym>CABY1</acronym>
  <official_title>Selective Depletion of C-reactive Protein by Therapeutic Apheresis (CRP Apheresis) After Elective Primary Coronary Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pentracor GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pentracor GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CABY1 study is conducted open, controlled, randomized and monocentric. The efficacy and&#xD;
      tolerability of CRP apheresis in patients undergoing elective primary coronary bypass surgery&#xD;
      is investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CABY1 is a clinical trial to study the reduction of C-reactive protein (CRP) by therapeutic&#xD;
      apheresis (CRP apheresis) in patients undergoing elective primary coronary bypass surgery.&#xD;
&#xD;
      The term therapeutic apheresis describes therapeutical procedures whose effect is based on&#xD;
      the elimination of blood components with a pathogenic function within the disease process.&#xD;
      Elimination takes place in adsorbers outside the body in an extracorporeal circuit. To remove&#xD;
      the pathogenic substances, blood plasma is separated from the circuit and passed through an&#xD;
      adsorber. The purified blood plasma is then reunited with the solid blood components and&#xD;
      returned to the patient.&#xD;
&#xD;
      The &quot;PentraSorb® CRP&quot; adsorber used for CRP apheresis is CE-certified. It serves for the&#xD;
      selective depletion of the C-reactive protein from human plasma.&#xD;
&#xD;
      As a cause of the damaging effect of the C-reactive protein it is assumed that the CRP as an&#xD;
      inflammatory mediator favours the destruction of cardiac muscle tissue (in conjunction with&#xD;
      complement) and has a negative influence on the regeneration of the traumatized tissue.&#xD;
&#xD;
      The aim of the CABY1 study is to investigate if the tissue damage of the heart can be reduced&#xD;
      by depletion of the C-reactive protein after elective coronary bypass surgery. A possible&#xD;
      protective effect of CRP apheresis will be determined from laboratory biomarkers (e.g.,&#xD;
      troponin I, CM-MB, IL-6) and cardiac events.&#xD;
&#xD;
      20 randomly selected patients receive apheresis treatments with a duration of 4-6 h each the&#xD;
      following 2-3 days after bypass surgery, the 20 patients of the controls do not receive&#xD;
      apheresis. The biomarkers required for the evaluation of the treatment success are determined&#xD;
      over a period of 4 days after surgery on the basis of the routine blood tests. Cardiac events&#xD;
      are documented until the patient is discharged.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tissue damage of the heart</measure>
    <time_frame>Every 24 hours for up to 96 hours after bypass surgery</time_frame>
    <description>Daily determination of the concentration of the biomarker Troponin I (hsTnI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of CRP apheresis</measure>
    <time_frame>24 hours after each apheresis</time_frame>
    <description>Incidence of expected and unexpected adverse effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac events</measure>
    <time_frame>Until the patient is discharged from the hospital, an average of 7 days</time_frame>
    <description>Documentation of cardiac events:&#xD;
Cardiac arrythmias&#xD;
Perioperative myocardial infarction (PMI)&#xD;
Cardiopulmonary resuscitation (CPR)&#xD;
Low cardiac output syndrome (LCOS)&#xD;
Re-surgery&#xD;
Percutaneous coronary intervention (PCI)&#xD;
Angina pectoris</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue damage of the heart with Procalcitonin</measure>
    <time_frame>Every 24 hours for 72 hours after bypass surgery</time_frame>
    <description>Daily determination of the concentration of:&#xD;
- Procalcitonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue damage of the heart with CK-MB</measure>
    <time_frame>Every 24 hours for 72 hours after bypass surgery</time_frame>
    <description>Daily determination of the concentration of:&#xD;
- Creatine kinase, MB fraction (CK-MB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue damage of the heart with Myoglobin</measure>
    <time_frame>Every 24 hours for 72 hours after bypass surgery</time_frame>
    <description>Daily determination of the concentration of:&#xD;
- Myoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue damage of the heart with Leukocytes</measure>
    <time_frame>Every 24 hours for 72 hours after bypass surgery</time_frame>
    <description>Daily determination of the concentration of:&#xD;
- Leukocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue damage of the heart with Interleukin-6</measure>
    <time_frame>Every 24 hours for 72 hours after bypass surgery</time_frame>
    <description>Daily determination of the concentration of:&#xD;
- Interleukin-6 (IL-6)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Post-cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Apheresis Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients receive 2 apheresis treatments at intervals of 24 ± 12 h (additionally to the standard therapy after bypass surgery). The first treatment starts within 24 h postoperatively. If the CRP concentration increases to at least 30 mg/L 6-18 h after the end of the second treatment, a third treatment is performed.&#xD;
For each treatment the 1 - 2.5-fold plasma void is processed. The duration of each treatment is 4-6 h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>17 patients of the control group receive the standard therapy after bypass surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRP apheresis</intervention_name>
    <description>Selective CRP apheresis by use of the PentraSorb-CRP adsorber</description>
    <arm_group_label>Apheresis Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  elective, isolated, primary coronary bypass surgery&#xD;
&#xD;
          -  2 or 3-fold CHD with or without main stem stenosis&#xD;
&#xD;
          -  Obtained LVEF (&gt; 30%, trans-oesophageal echocardiography (TEE) or angiography)&#xD;
&#xD;
          -  Heart-lung machine (HLM; 'two-stage' cannulation)&#xD;
&#xD;
          -  Antegrade Bretschneider cardioplegia&#xD;
&#xD;
          -  Mild hypothermia (32 °C)&#xD;
&#xD;
          -  Standard anesthesia (isoflurane)&#xD;
&#xD;
          -  Intraoperative standard protocol (500 mg ASA after 2 h, low dose heparinization after&#xD;
             4 h)&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  legal capacity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Preoperatively&#xD;
&#xD;
          -  PCI (within last 2 weeks)&#xD;
&#xD;
          -  Renal insufficiency (creatinine &gt; 1.3 mmol/L or requiring dialysis)&#xD;
&#xD;
          -  Combination interventions&#xD;
&#xD;
          -  Re-surgery&#xD;
&#xD;
          -  Emergency of urgent surgery indication&#xD;
&#xD;
          -  Acute coronary syndrome (IAP, NSTEMI, STEMI)&#xD;
&#xD;
          -  Preoperatively positive hs-troponin I &gt; 40 ng/ml&#xD;
&#xD;
          -  Chronic arterial fibrillation&#xD;
&#xD;
          -  Acute infectious disease (body temperature &gt; 38.0°C)&#xD;
&#xD;
          -  Systolic blood pressure &lt; 100 mmHg&#xD;
&#xD;
          -  Known hypersensitivity to therapeutic apheresis&#xD;
&#xD;
          -  Cardiac shock&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Participation in other interventional trial&#xD;
&#xD;
        During surgery&#xD;
&#xD;
          -  Radialis removal&#xD;
&#xD;
          -  Coronary TEA (if blood flow within bypass &lt; 20 ml/min)&#xD;
&#xD;
          -  Off-pump&#xD;
&#xD;
          -  Hemofiltration&#xD;
&#xD;
          -  Combination intervention (e.g. mitral valve reconstruction, LAA)&#xD;
&#xD;
          -  Maze procedure&#xD;
&#xD;
          -  Bypass low-flow closure, ECG changes&#xD;
&#xD;
          -  Antithrombotic therapy (intraoperative clopidogrel and/or aspirin)&#xD;
&#xD;
          -  Second HLM&#xD;
&#xD;
          -  Second cardioplegic cardiac arrest&#xD;
&#xD;
          -  Intraaortal balloon pumping / balloon pulsation (IABP)&#xD;
&#xD;
          -  Extracorporeal membrane oxygenation (ECMO)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Thielmann, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westdeutsches Herz- und Gefäßzentrum Essen, Klinik für Thorax- und Kardiovaskuläre Chirurgie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Burghard Thiesen, Dr.</last_name>
    <phone>004915255318960</phone>
    <email>thiesen@pentracor.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinik für Thorax- und Kardiovaskuläre Chirurgie</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Thielmann, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

